What is Bleomycin?
Bleomycin is a cytotoxic glycopeptide antibiotic used as chemotherapy for germ cell tumors, lymphomas (including Hodgkin lymphoma), and head and neck cancers, with its primary mechanism involving DNA strand breaks through iron-mediated free radical generation. 1
Mechanism of Action
Bleomycin works through a unique DNA-damaging mechanism that requires three cofactors: a transition metal (iron), oxygen, and a one-electron reductant 2. The drug binds to guanosine-cytosine-rich portions of DNA through its "S" tripeptide and bithiazole rings, which partially intercalate into the DNA helix 3. Five nitrogen atoms arranged in a square-pyramidal configuration bind iron, which then binds molecular oxygen to produce highly reactive free radicals. These radicals cause DNA single-strand breaks at 3'-4' bonds in deoxyribose, yielding free base propenals (especially thymine), with cytotoxicity that is cell-cycle-phase specific for G2 phase 3.
Beyond DNA damage, bleomycin can induce lipid peroxidation independent of its DNA effects, which may be particularly important in causing lung toxicity 4.
Clinical Indications
The drug demonstrates potent antitumor activity against:
- Germ cell tumors (testicular cancer) 5
- Hodgkin lymphoma 6, 7
- Head and neck cancers 2, 8
- Various other lymphomas 2
Administration
Bleomycin can be administered via multiple routes: intravenous, intramuscular, or subcutaneous injection 1. Typical schedules involve weekly bolus or short infusion, with no evidence supporting superiority of bolus versus continuous administration 5. The drug should be administered under direct supervision of clinicians familiar with its use and toxicities 5.
Critical Toxicity: Pulmonary Complications
The most serious limitation of bleomycin therapy is pulmonary toxicity, which can progress to irreversible lung fibrosis and is more common in patients over 70 years of age 1. This occurs because skin and lung tissues have low concentrations of bleomycin hydrolase enzyme (a cysteine proteinase that inactivates the drug), making them uniquely sensitive to toxicity 3.
Key Risk Factors for Pulmonary Toxicity:
- Age over 40 (especially over 70) 5, 1
- Significant smoking history 5
- Reduced renal function 5
- Pre-existing lung disease, particularly fibrosis 5
- Cumulative dose >300 units 5
Monitoring for Toxicity:
Cough is the most sensitive symptom for predicting bleomycin pulmonary toxicity, followed by dyspnea 5. When toxicity is suspected:
- First-line investigation: High-resolution CT (HRCT) chest 5
- Chest X-ray has extremely low sensitivity and should NOT be used 5
- Pulmonary function tests (PFTs) should not be used as first-line investigation but may aid in diagnostic uncertainty 5
- A toxicity checklist should be used before and after every cycle 5
If lung toxicity is confirmed, cessation of therapy may reverse lung damage, while continuing bleomycin may worsen toxicity 5. The decision to continue should always be a consultant-level decision made in a multidisciplinary setting with experienced oncologists and radiologists 5. It is safer to omit an individual dose in patients with new cough or dyspnea than to risk exacerbating toxicity 5.
Treatment of Confirmed Toxicity:
All CT-confirmed diagnoses should be considered for oral prednisolone 0.5 mg/kg for 7 days with taper 5. Infection should always be considered as it may mimic, coexist with, or drive bleomycin-related lung toxicity 5.
Pharmacokinetics and Dosing Considerations
Bleomycin is rapidly eliminated primarily by renal excretion (approximately 50% of dose), with a normal half-life of 2-4 hours 3. In patients with creatinine clearance <50 mL/min or extensive prior cisplatin therapy, the half-life can extend up to 21 hours, requiring dose adjustments 1, 3. The drug is known to be substantially excreted by the kidney, making elderly patients with decreased renal function at higher risk for toxic reactions 1.
Contraindications
There are no absolute contraindications to bleomycin use 5. However, caution should be exercised with increasing age, significant smoking history, reduced renal function, and pre-existing lung disease—particularly when multiple risk factors are present 5.
Post-Treatment Monitoring
All patients receiving more than 300 units of bleomycin should receive a post-treatment CT scan 5. Further investigations should be symptom-led 5.